Title/ Funkce Sample Clauses

Title/ Funkce. (must authorized to sign on Institution’s behalf)/(musí se jednat o podpis oprávněného zástupce Poskytovatele): Signature/ Podpis: Date/ Datum: 5.8.2019 ACKNOWLEDGED AND AGREED BY THE INVESTIGATOR / NA DŮKAZ SOUHLASU PěIPOJUJE SVŮJ PODPIS ZKOUŠEJÍCÍ Name/ Jméno: Signature/ Podpis: Date/ Datum: 2.8.2019 ACKNOWLEDGED AND AGREED BY Jazz Pharmaceuticals Ireland Limited / NA DŮKAZ SOUHLASU PěIPOJUJE SVŮJ PODPIS OPRÁVNĚNÝ ZÁSTUPCE SPOLEČNOSTI Jazz Pharmaceuticals Ireland Limited By/ Jméno: Title/ Funkce: Signature/ Podpis: Date/ Datum: Attachments: Přílohy: Attachment A - Budget and payment schedule Příloha A – Rozpočet a platební přehled Attachment B- Power of attorney/delegation letter of IQVIA Příloha B – Plná moc / delegační dopis pro IQVIA ATTACHMENT A PěÍLOHA A BUDGET & PAYMENT SCHEDULE ROZPOČET & PLATEBNÍ PěEHLED
AutoNDA by SimpleDocs
Title/ Funkce. Director / ěeditel (must authorized to sign on Institution's behalf)/(musí se jednat o podpis oprávněného zástupce Poskytovatle): Signature/ Podpis: Date/ Datum: 11.12.2020 ACKNOWLEDGED AND AGREED BY THE INVESTIGATOR / NA DŮKAZ SOUHLASU PěIPOJUJE SVŮJ PODPIS ZKOUŠEJÍCÍ Name/ Jméno: Signature/ Podpis: Date/ Datum: 11.12.2020 Signed by IQVIA RDS Czech Republic s.r.o., under a Power of Attorney dated 18 June 2020, in the name of GlaxoSmithKline Research and Development Limited / Podepsáno IQVIA RDS Czech Republic s.r.o., na základě Plné moci vystavené dne 18. června 2020, jménem GlaxoSmithKline Research and Development Limited Name/ Jméno: Czech Republic _Clinical Trial Agreement _INST & INV_ 8 April2020 / GSK-IQVIA Global Template – 03Mar2020 Clinical Trial Agreement / Smlouva o klinickém hodnocení GlaxoSmithKline Research and Development Limited / 207499 Fakultní nemocnice Hradec Králové / CONFIDENTIAL / DŮVĚRNÉ Signature/ Podpis: Date/ Datum: 10.12.2020 Attachments: Přílohy: Attachment ABudget and payment schedule Příloha A – Rozpočet a platební přehled Attachment B – Power of attorney/delegation letter of IQVIA Příloha B – Plná moc/delegační dopis pro IQVIA Czech Republic _Clinical Trial Agreement _INST & INV_ 8 April2020 / GSK-IQVIA Global Template – 03Mar2020 Clinical Trial Agreement / Smlouva o klinickém hodnocení GlaxoSmithKline Research and Development Limited / 207499 Fakultní nemocnice Hradec Králové CONFIDENTIAL / DŮVĚRNÉ ATTACHMENT A PěÍLOHA A Budget & Payment Schedule Rozpočet a rozpis plateb
Title/ Funkce. Director / ředitel (must authorized to sign on Institution’s behalf) / (musí se jednat o podpis oprávněného zástupce Poskytovatele): Signature/ Podpis: Date/ Datum: 10. 8. 2019 ACKNOWLEDGED AND AGREED BY THE INVESTIGATOR / NA DŮKAZ SOUHLASU PěIPOJUJE SVŮJ PODPIS ZKOUŠEJÍCÍ Name/ Jméno: Signature/ Podpis: Date/ Datum: 19. 8. 2019 Signed by IQVIA RDS Czech Republic s.r.o., under a Power of Attorney dated 1 March 2019, on behalf of of Lyra Therapeutics, Inc. / Podepsáno IQVIA RDS Czech Republic s.r.o., na základě Plné moci vystavené dne 1. března 2019, jménem Lyra Therapeutics, Inc. Name/ Jméno: Signature/ Podpis: Date/ Datum: 31. 7. 2019 Attachments: Přílohy: Attachment ABudget and payment schedule Attachment B – Power of attorney/delegation letter of IQVIA Příloha A – Rozpočet a platební přehled Příloha B – Plná moc/delegační dopis pro IQVIA LYR-210-2018-002_Czech Republic_CTA Template_Institution and Investigator_draft_14Jan2019 Clinical Trial Agreement / Smlouva o klinickém hodnocení Lyra Therapeutics, Inc. / LYR-201-2018-002 Fakultní nemocnice Hradec Králové / ATTACHMENT A PěÍLOHA A
Title/ Funkce. Director / Ředitel (must authorized to sign on Institution’s behalf)/(musí se jednat o podpis oprávněného zástupce Zdravotnického zařízení be): Signature/ Podpis: Date/ Datum: ACKNOWLEDGED AND AGREED BY THE INVESTIGATOR/ NA DŮKAZ SOUHLASU PŘIPOJUJE SVŮJ PODPIS ZKOUŠEJÍCÍ Name/ Jméno: Signature/ Podpis: Date/ Datum: Signed by IQVIA RDS Czech Republic s.r.o., under a Letter of Delegation dated 31 January 2019, in the name of ABIVAX / Podepsáno IQVIA RDS Czech Republic s.r.o., na základě Delegačního dopisu vystaveného dne 31. ledna 2019, jménem ABIVAX Name/ Jméno: Signature/ Podpis: Date/ Datum: Attachment A Příloha A Budget & Payment Schedule Rozpočet & Platební Přehled Attachment C Příloha C
Title/ Funkce. Director / ředitel (must authorized to sign on Institution's behalf)/(musí xx xxxxxx o podpis oprávněného zástupce Zdravotnického zařízení) Signature/ Podpis: Date/ Datum: ACKNOWLEDGED AND AGREED BY THE Investigator / NA DŮKAZ SOUHLASU PŘIPOJUJE SVŮJ PODPIS Zkoušející Name/ Xxxxx: Signature/ Podpis: Date/ Datum: ATTACHMENT A PŘÍLOHA A Budget & Payment Schedule Rozpočet & Platební Přehled
Title/ Funkce. Director / šeditel (must authorized to sign on Institution’s behalf)/(musí se jednat o podpis oprávněného zástupce Poskytovatele): Signature/ Podpis: Date/ Datum: 7. 6. 2019 ACKNOWLEDGED AND AGREED BY THE INVESTIGATOR / NA DUKAZ SOUHLASU PǍIPOJUJE SVUJ PODPIS ZKOUŠEJÍCÍ Name/ Jméno: Signature/ Podpis: Date/ Datum: 6. 6. 2019 ACKNOWLEDGED AND AGREED BY THE SPONSOR / NA DUKAZ SOUHLASU PǍIPOJUJE SVUJ PODPIS ZADAVATELE Name/ Jméno: Title/ Funkce: Signature/ Podpis: Date/ Datum: 27. 5. 2019 Name/ Jméno: Title/ Funkce: Signature/ Podpis: Date/ Datum:
Title/ Funkce. (must authorized to sign on Institution’s behalf)/(musí se jednat o podpis oprávneného zástupce Poskytovatele): Signature/ Podpis: Date/ Datum: 18. 1. 2019 ACKNOWLEDGED AND AGREED BY THE INVESTIGATOR / NA DŮKAZ SOUHLASU PǍIPOJUJE SVŮJ PODPIS ZKOUŠEJÍCÍ Name/ Jméno: Signature/ Podpis:
AutoNDA by SimpleDocs
Title/ Funkce. Director / šeditel (must authorized to sign on Institution's behalf)/(musí se jednat o podpis oprávneného zástupce Poskytovatele) Signature/ Podpis: Date/ Datum: 8. 2. 2019 ACKNOWLEDGED AND AGREED BY THE INVESTIGATOR/ NA DUKAZ SOUHLASU PǍIPOJUJE SVUJ PODPIS ZKOUŠEJÍCÍ Name/ Jméno: Signature/ Podpis: Date/ Datum: 7. 2. 2019 Signed by IQVIA RDS Czech Republic s.r.o., under a Power of Attorney dated 12 October 2018, in the name of InflaRx GmbH / Podepsáno IQVIA RDS Czech Republic s.r.o., na základe Plné moci vystavené dne 12. šxxxx 0000, xxxxxx XnflaRx GmbH Name/ Jméno: Signature/ Podpis:

Related to Title/ Funkce

  • Civil Rights Title Vi Assurances A. Compliance with Nondiscrimination Requirements During the performance of this Contract, the Design Professional, for itself, its assignees, and successors in interest (hereinafter referred to as the “Design Professional”) agrees as follows:

  • Title Passage All right, title, and interest in and to any Included Timber shall remain in Forest Ser- vice until it has been cut, Scaled, removed from Sale Area or other authorized cutting area, and paid for, at which time title shall vest in Purchaser. For purposes of this Subsection, timber cut under cash deposit or pay- ment guarantee under B4.3 shall be considered to have been paid for. Title to any Included Timber that has been cut, Scaled, and paid for, but not removed from Sale Area or other authorized cutting area by Purchaser on or prior to Termination Date, shall remain in Forest Service.

  • Title Matters Seller agrees to share equally with Buyer the closing costs and the cost of a title insurance company's commitment for and policy of title insurance. Buyer shall pay for any lender’s/mortgagee’s/instrument holder’s title insurance coverage. The title insurance company will furnish a copy of the commitment for title insurance and copies of all of the exception documents referred to therein (hereafter collectively referred to as the “Title Commitment”) to Seller, Buyer, Buyer’s lender and the listing/selling broker as promptly as possible. The Title Commitment shall show a merchantable title vested in Seller, subject to easements, restrictions and protective covenants of record, right-of-way’s, setbacks, tenant rights, trees, fences, ordinances and regulations, unmatured and future assessments, restrictions and protective covenants of record, provided no forfeiture provisions as contained therein, encroachments and overlaps, zoning laws, ordinances and regulations, those exceptions which are standard to a policy of title insurance in the State of Kansas or as specified herein, and those matters attaching to the title by reason of Buyer taking title to the real property. Buyer shall have a period of five (5) days following receipt of the Title Commitment (the “Objection Period”) in which to examine the Title Commitment and advise Seller in writing of any objections ("Title Objections") the Buyer may have to Seller's title as shown in the Title Commitment. Seller shall then have a period of five (5) days in which to notify Buyer in writing of those Title Objections it elects to cure. In the event Seller elects to cure less than all of the Title Objections, Buyer shall have the right to terminate this Agreement by giving Seller written notice thereof within five (5) days of its receipt of Seller's notice, in which case the Xxxxxxx Money shall be returned to Buyer, and thereafter neither party shall have any further obligation hereunder. In the event Buyer does not terminate this Agreement, Seller shall have until Closing ("Cure Period") in which to cure the Title Objections the Seller has elected to cure, which the Buyer Agrees to extend for an additional 45 days in the event Seller has initiated a lawsuit to cure the title objection or objections. Title Objections may also be cured in accordance with applicable current titled standards in the Kansas Title Standards Handbook.

  • TITLE VI ASSURANCES The requirements and terms of the United States Department of Transportation Title VI program, as revised from time to time, are incorporated into this Contract for all purposes. Engineer has reviewed Exhibit “J”, and shall comply with its terms and conditions.

  • Title Examination Within thirty (30) days after Purchaser’s exercise of the Option, Purchaser shall have the right to obtain, at Purchaser’s expense, a current survey of the Property (the “Updated Survey”) and an ALTA Title Commitment for the Property from a title company acceptable to Purchaser (the “Title Company”), setting forth the status of title to the Property, and showing all liens, claims, encumbrances, reservations, restrictions and other matters, if any, relating to the Property (the “Title Commitment”), including legible copies of all encumbrances, restrictive covenants and other documents evidencing exceptions to said Title Commitment (the “Exception Documents”). If the Title Commitment and/or Updated Survey reveals any exception(s) to title to which Purchaser objects (a “Title Objection”) and is(are) not either (i) listed as title exceptions in the title insurance policy and/or survey obtained by Seller in connection with the closing of the Mezzanine Loan and/or (ii) permitted by this Agreement (collectively, the “Permitted Encumbrances”), Purchaser may notify Seller in writing that it would like Seller to cure or remove such Title Objections. Seller shall have the right, but not the obligation (except as set forth below), to remedy or cure any such Title Objection(s) during the twenty (20) day period following Seller’s receipt thereof (the “Cure Period”). Purchaser shall have the continuing right to have such title examination and Title Commitments updated from time to time, and to obtain updates to the Survey, and to give Seller written notice of any Title Objections appearing of record, or otherwise created, after the effective date of the initial Title Commitment and being revealed by any title examination, Survey or investigation of the Property, and Purchaser shall be entitled to object (in the same manner as set forth hereinabove) to matters shown by the updated Title Commitments or updated Survey or investigations. Seller shall have the right, but not the obligation (except as set forth below), to remedy those Title Objections identified by Purchaser to the satisfaction of Purchaser within twenty (20) days after Purchaser’s notice. If any of the Title Objections are not so cured or remedied, or provision satisfactory to Purchaser made therefor, prior to any closing date selected by Purchaser, then Purchaser, at its election, shall have the right and option to either: (a) accept title to the Property subject to said uncured Title Objections that Purchaser elects to accept, and any Title Objection accepted by Purchaser in writing shall become part of the Permitted Encumbrances; or (b) terminate this Agreement by written notice to Seller, in which event, immediately upon receipt of said notice, this Agreement shall terminate, be null and void and of no further force or effect. Notwithstanding the foregoing, Seller, at Seller’s sole cost and expense, shall be obligated to cure or remove at or before Closing all mortgages, deeds of trust, deeds to secure debt, judgments liens, mechanics and materialman’s liens, and other monetary liens against the Property, whether or not Purchaser objects thereto, and Purchaser shall credit the cost to cure, satisfy, release and remove such matters against the Purchase Price provided the same is actually paid by Purchaser or Title Company on Seller’s behalf. In addition, Seller shall not allow any easements, liens, leases, licenses, permits or other encumbrances to be placed on or granted with respect to the Property, nor shall Seller convey any rights in the Property, without the prior written consent of Purchaser, except to the extent expressly permitted, or consented to in writing by Purchaser under the Mezzanine Loan Documents. If any such prohibited easements, liens, leases, licenses, permits or other encumbrances arise after the Effective Date, notwithstanding any other term or provision of this Agreement to the contrary, Seller shall, at its sole cost and expense, cure, satisfy, release and remove such matters prior to Closing; provided, however, that any easements or encumbrances that are taken by eminent domain shall be governed by the terms of Section 5 immediately below.

  • Title IX Hill College strives to maintain a work and educational environment free from discrimination, sexual harassment, sexual assault, stalking, rape, dating and domestic violence, and related retaliation in accordance with applicable federal and state laws. Students may contact the Office of Student Services, Xxxx of Students, Campus Safety, Campus Security Authority (CSAs) or Title IX Coordinator for assistance with reporting a complaint or may file a complaint online from the Hill College website. The Title IX Coordinator: Xx. Xxxxx Xxxxx Director of Human Resources 000 Xxxxx Xxxxx Hillsboro, TX 76645 254‐659‐7731 or xxxxxx@xxxxxxxxxxx.xxx

  • TITLE VI REQUIREMENTS H-GAC in accordance with the provisions of Title VI of the Civil Rights Act of 1964 (78 Xxxx. 000, 00 X.X.X. §§ 0000x to 2000d-4) and the Regulations, hereby notifies all bidders that it will affirmatively ensure that any disadvantaged business enterprises will be afforded full and fair opportunity to submit in response to this Agreement and will not be discriminated against on the grounds of race, color, or national origin in consideration for an award.

  • Initial Assessment A Board-designated Administrator shall determine whether the alleged conduct merits an investigation.

  • Title Objections Seller shall request Escrow Agent to cause to be delivered to Buyer a preliminary title report (the "Preliminary Report") from a title company affiliated with the Escrow Agent (the "Title Company"), showing the status of Seller’s title to the Property, together with complete and legible copies of all documents shown therein as exceptions to title ("Exceptions"). Buyer shall have until the date that is five (5) days after the Title Company delivers the Preliminary Report and Exceptions to Buyer within which to give notice in writing to Seller of any objection to such title or to any liens or encumbrances affecting the Property. Within five (5) days after receipt of such notice from Buyer, Seller shall give Buyer written notice of whether it is willing and able to remove the objected-to Exceptions. Without the need for objection by Buyer, Seller shall, with respect to liens and encumbrances that can be satisfied and released by the payment of money, eliminate such exceptions to title on or before Closing. Within five (5) days after receipt of such notice from Seller (the "Title Contingency Date"), Buyer shall elect whether to: (i) purchase the Property subject to those objected-to Exceptions which Seller is not willing or able to remove; or (ii) terminate this Agreement. If Buyer fails to give Seller notice of Buyer’s election, then such inaction shall be deemed to be Buyer’s election to terminate this Agreement. On or before the Closing Date (defined below), Seller shall remove all Exceptions to which Buyer objects and which Seller agrees, or is deemed to have agreed, Seller is willing and able to remove. All remaining Exceptions set forth in the Preliminary Report and those Exceptions caused by or agreed to by Buyer shall be deemed "Permitted Exceptions."

  • Title and Survey (a) The Seller shall order and cause to be delivered to each of the Buyer and the Seller a commitment for the Title Policy from the Title Company, together with all underlying title exception documents. The Buyer shall, at its expense, order and cause to be delivered to each of the Buyer and the Seller, an ALTA survey of the Property. After receipt of the survey and the title commitment, the Buyer shall notify the Seller of any defects in title or survey shown by such commitment and/or ALTA survey that the Buyer is unwilling to accept. Within 5 days after such notification, the Seller shall notify the Buyer whether the Seller is willing to cure such defects; the Seller’s failure to so notify the Buyer shall be deemed to be the Seller’s refusal to cure all such defects (except for any defects consisting of those items in the last sentence of this SECTION 3.2 below expressly required to be cured by the Seller). The Seller may cure any defect by causing the Title Company, at the Seller’s sole cost and expense, to omit such defect as an exception to the Title Policy or to “insure over” such defect to the Buyer’s reasonable satisfaction. If the Seller is willing to cure such defects, the Seller shall act promptly, diligently and use commercially reasonable efforts to cure such defects at its expense. Subject to those items below expressly required to be cured by the Seller, if the Seller is unwilling or unable to cure any other such defects by Closing (or fails to notify Buyer and therefore has elected not to cure such defects), then the Buyer shall elect, within 5 days after written notice thereof from the Seller to the Buyer (or within 5 days after the Seller’s time for giving notice has expired without any notice from the Seller), by giving the Seller written notice that the Buyer either (i) waives such defects and shall proceed to Closing without any abatement in the Purchase Price with respect thereto, or (ii) terminates this Agreement and shall be entitled to receive a full and immediate refund of the Xxxxxxx Money and, upon return of the Xxxxxxx Money, this Agreement shall terminate and the Buyer and the Seller shall have no further rights, liabilities or obligations hereunder (except as expressly survive the termination of this Agreement). In the event that the Buyer does not make such election within the applicable time frame, the Buyer shall be deemed to have elected to waive any such defects pursuant to clause (i) above. Subject to those items below expressly required to be cured by the Seller, all title matters not objected to by the Buyer during the Study Period (or objected to but which the Seller declines, or is deemed to decline, to cure as provided above without the Buyer thereafter electing to terminate this Agreement) shall be deemed “Permitted Title Exceptions.” Notwithstanding the foregoing, if any such defects of title consist of mortgages or deeds of trust, any other monetary liens and/or tax liens (other than liens for taxes not yet due and payable), the Buyer shall be deemed to have notified the Seller that the Buyer is unwilling to accept such defects and the Seller covenants and agrees that at or prior to Closing the Seller shall cure by payment, bonding, or escrow deposit acceptable to the Title Company (and the Escrow Agent is authorized to pay and discharge at Closing from the Seller’s proceeds, if not so cured) and cause to be cancelled and discharged such monetary title defects.

Time is Money Join Law Insider Premium to draft better contracts faster.